Medicine and Dentistry
Ranibizumab
100%
Macular Edema
100%
Network Meta-Analysis
100%
Branch Retinal Vein Occlusion
100%
Implant
44%
Dexamethasone
44%
Monotherapy
33%
Randomized Controlled Trial
33%
Intraocular Pressure
22%
Laser Coagulation
11%
Diabetic Retinopathy
11%
Bevacizumab
11%
Best Corrected Visual Acuity
11%
Endothelial Cell Growth Factor
11%
Systematic Review
11%
Triamcinolone
11%
Pharmacology, Toxicology and Pharmaceutical Science
Macular Edema
100%
Ranibizumab
100%
Branch Retinal Vein Occlusion
100%
Aflibercept
66%
Implant
44%
Dexamethasone
44%
Randomized Controlled Trial
33%
Monotherapy
33%
Triamcinolone
11%
Diabetic Retinopathy
11%
Bevacizumab
11%
Endothelial Cell Growth Factor
11%
Keyphrases
Comparative Efficacy
100%
Aflibercept
66%
Dexamethasone Implant
33%
Ocular Hypertension
22%
Pro Re Nata
11%
Increased Intraocular Pressure
11%
Dexamethasone 0.7 Mg
11%
Triamcinolone
11%
Neuroscience
Ranibizumab
100%
Aflibercept
66%
Ocular Hypertension
22%
Endothelial Cell Growth Factor
11%
Triamcinolone
11%